- Conference Call Today at 9 a.m. ET - AUSTIN, Texas , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2021 .

- Call-in on Tuesday, August 3rd at 9 a.m. ET - AUSTIN, Texas , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the

Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 Months Cognition Improved 3.0 Points on ADAS-Cog at 9 Months ( p

Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 Months Robust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p

SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 44% (p=0.02) Respectively Plasma

- On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation - - On Thursday, July 29 th , New Clinical Data for Simufilam to be Featured in a Podium Presentation - AUSTIN, Texas , July 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.

Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer’s Disease AUSTIN, Texas , June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced

Open-label Study Completes Patient Enrollment Cognition Maintenance Study Initiated May 2020 , now 30% Enrolled 6-month Biomarker Data to be Presented at AAIC Conference in July 9-month Safety & Cognition Data to be Presented at AAIC Conference   Clinical Results with SavaDx to be Presented at AAIC

AUSTIN, Texas , June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference , a virtual event taking

- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals – AUSTIN, Texas , June 14, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced